Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyDiseaseAmpullary CancerSmall Bowel CarcinomaSubgroupICD10C17.-C24.1MeSHCommon Bile Duct NeoplasmsDuodenal NeoplasmsIleal NeoplasmsJejunal NeoplasmsSequenceChemotherapyChemo-substanceBevacizumabCapecitabineOxaliplatinChemo-substanceBevacizumabCapecitabineOxaliplatinChemo-substanceBevacizumabCapecitabineOxaliplatinChemo-substanceBevacizumabCapecitabineOxaliplatinNo. Substances3 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronNo. Substances3Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionpalliativeRisksAbdominal PainAnemia Hb below 10g/dlDiarrheaEmetogenicity (MASCC/ESMO)FatigueHypertensionNeutropeniaThrombocytopenia below 50 000/µl only studiesPublicationAuthorGulhati PDiseaseAdenokarzinom des Dünndarms oder der Papilla Vateri, ECOG 0-2OriginHematology/Oncology Fellowship Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TexasProtocols in Revision 1 protocol foundProtocols under revision.CAPOX (Capecitabine 750 / Oxaliplatin130) / Bevacizumab 7.5, Small bowel Cancer or Ampullary Cancer (PID490 V1.1)
